• 4/6/2006
  • Phoenix, AZ
  • staff
  • News5Phoenix (www.kpho.com)

Results from preclinical studies show that the anti-cancer compound AV-412 — a EGFR/HER2 kinase inhibitor — demonstrated anti-tumor activity against tumors that were both sensitive and resistant to Tarceva (erlotinib) and Iressa (gefitinib).

The findings were announced Tuesday by AVEO Pharmaceuticals, Inc. at the annual meeting of the American Association for Cancer Research.

During the preclinical studies, the drug was tested in non-small cell lung cancer cell lines and in mice.

The company says AV-412’s mechanism of action may prove beneficial to patients with non-small cell lung cancer, metastatic breast cancer, pancreatic cancer, head and neck cancer, and hormone refractory prostrate cancer.

The drug is slated to enter clinical trials this year to test i6s safety and efficacy in treating solid tumors.